FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313489080> ?p ?o ?g. }

• W4313489080 endingPage "546" @default.
• W4313489080 startingPage "534" @default.
• W4313489080 abstract "We have shown that decursin, a coumarin compound, induces cell cycle arrest and apoptosis in human prostate cancer cells (PCa); however, its molecular mechanisms are largely unexplored. We studied the mechanisms associated with its anticancer activity in advanced human prostate carcinoma cells. We found that decursin inhibited epidermal growth factor receptor (EGFR) signaling by inhibiting its activating phosphorylation at tyrosine 1068 residue in DU145 and 22Rv1 cells. This inhibition of EGFR was associated with the downregulation of ERK1/2 phosphorylation. Both EGFR and ERK1/2 are known to be deregulated/activated in many human malignancies. Consistent with our earlier study, decursin (25-100 µM) treatment for 24-72 h inhibited DU145 cell proliferation by 49%-87% (p < 0.001) which was associated with strong G1 phase arrest and cell death. It also decreased (p < 0.001) the number of surviving colonies. Decursin moderately increased the expression of Rb-related proteins p107 and p130 but decreased the levels of E2F family transcription factors including E2F-3, E2F-4 and E2F-5. Further, decursin strongly inhibited the growth of androgen-dependent prostate carcinoma 22Rv1 cells from 61% to 79% (p < 0.001) and arrested these cells at G1 phase via induction of cyclin-dependent kinase inhibitor p27/Kip1 and downregulation of CDK2 and CDK4 protein expression. Additionally, EGFR inhibitor erlotinib- and EGF ligand-modulated EGFR activation validated EGFR signaling as a target of decursin-mediated cell growth inhibition and cytotoxicity. Decursin decreased EGF ligand-induced phosphorylation of EGFR (Y-1068) as well as activation of its downstream mediator, ERK1/2. Furthermore, inhibitory targeting of EGFR-ERK1/2 axis by combinatorial treatment of decursin and erlotinib further sensitized DU145 cells for the decursin-induced growth inhibition and cell death. Overall, these findings strongly suggest that anticancer efficacy of decursin against human PCa involves inhibitory targeting of EGFR-ERK1/2 signaling axis, a pathway constitutively active in advanced PCa." @default.
• W4313489080 created "2023-01-06" @default.
• W4313489080 creator A5017221987 @default.
• W4313489080 creator A5034673599 @default.
• W4313489080 creator A5056436394 @default.
• W4313489080 creator A5061526412 @default.
• W4313489080 creator A5075560543 @default.
• W4313489080 creator A5084515109 @default.
• W4313489080 date "2023-01-03" @default.
• W4313489080 modified "2023-10-02" @default.
• W4313489080 title "Decursin inhibits EGFR‐ERK1/2 signaling axis in advanced human prostate carcinoma cells" @default.
• W4313489080 cites W1749733472 @default.
• W4313489080 cites W1958175297 @default.
• W4313489080 cites W1974329776 @default.
• W4313489080 cites W1979876446 @default.
• W4313489080 cites W1992708996 @default.
• W4313489080 cites W1992913621 @default.
• W4313489080 cites W1993624611 @default.
• W4313489080 cites W1999072012 @default.
• W4313489080 cites W2000754726 @default.
• W4313489080 cites W2003473186 @default.
• W4313489080 cites W2005075550 @default.
• W4313489080 cites W2012147443 @default.
• W4313489080 cites W2015675085 @default.
• W4313489080 cites W2026241762 @default.
• W4313489080 cites W2041603571 @default.
• W4313489080 cites W2049562411 @default.
• W4313489080 cites W2050842762 @default.
• W4313489080 cites W2053008501 @default.
• W4313489080 cites W2059938519 @default.
• W4313489080 cites W2062289724 @default.
• W4313489080 cites W2064293531 @default.
• W4313489080 cites W2071333117 @default.
• W4313489080 cites W2074965343 @default.
• W4313489080 cites W2075066807 @default.
• W4313489080 cites W2081365151 @default.
• W4313489080 cites W2082162427 @default.
• W4313489080 cites W2082382637 @default.
• W4313489080 cites W2082631974 @default.
• W4313489080 cites W2088516053 @default.
• W4313489080 cites W2100914244 @default.
• W4313489080 cites W2108215899 @default.
• W4313489080 cites W2109968725 @default.
• W4313489080 cites W2114871525 @default.
• W4313489080 cites W2124009159 @default.
• W4313489080 cites W2133575920 @default.
• W4313489080 cites W2136578059 @default.
• W4313489080 cites W2138910230 @default.
• W4313489080 cites W2140093748 @default.
• W4313489080 cites W2140563811 @default.
• W4313489080 cites W2149188297 @default.
• W4313489080 cites W2152037201 @default.
• W4313489080 cites W2157824687 @default.
• W4313489080 cites W2166505025 @default.
• W4313489080 cites W2275518486 @default.
• W4313489080 cites W2283275285 @default.
• W4313489080 cites W2545169478 @default.
• W4313489080 cites W2727380696 @default.
• W4313489080 cites W2783078317 @default.
• W4313489080 cites W2797468522 @default.
• W4313489080 cites W2889646458 @default.
• W4313489080 cites W2912413839 @default.
• W4313489080 cites W2916721669 @default.
• W4313489080 cites W3018450372 @default.
• W4313489080 doi "https://doi.org/10.1002/pros.24482" @default.
• W4313489080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36597263" @default.
• W4313489080 hasPublicationYear "2023" @default.
• W4313489080 type Work @default.
• W4313489080 citedByCount "0" @default.
• W4313489080 crossrefType "journal-article" @default.
• W4313489080 hasAuthorship W4313489080A5017221987 @default.
• W4313489080 hasAuthorship W4313489080A5034673599 @default.
• W4313489080 hasAuthorship W4313489080A5056436394 @default.
• W4313489080 hasAuthorship W4313489080A5061526412 @default.
• W4313489080 hasAuthorship W4313489080A5075560543 @default.
• W4313489080 hasAuthorship W4313489080A5084515109 @default.
• W4313489080 hasConcept C104317684 @default.
• W4313489080 hasConcept C11960822 @default.
• W4313489080 hasConcept C121608353 @default.
• W4313489080 hasConcept C126322002 @default.
• W4313489080 hasConcept C127561419 @default.
• W4313489080 hasConcept C134018914 @default.
• W4313489080 hasConcept C170493617 @default.
• W4313489080 hasConcept C185592680 @default.
• W4313489080 hasConcept C190283241 @default.
• W4313489080 hasConcept C199835354 @default.
• W4313489080 hasConcept C2776362946 @default.
• W4313489080 hasConcept C2776438761 @default.
• W4313489080 hasConcept C2779438470 @default.
• W4313489080 hasConcept C2779723316 @default.
• W4313489080 hasConcept C2780192828 @default.
• W4313489080 hasConcept C29537977 @default.
• W4313489080 hasConcept C502942594 @default.
• W4313489080 hasConcept C55493867 @default.
• W4313489080 hasConcept C62112901 @default.
• W4313489080 hasConcept C71924100 @default.
• W4313489080 hasConcept C86803240 @default.
• W4313489080 hasConcept C95444343 @default.

• next